Floatz logo

Daratumumab

Acquired Hemophilia A

Institute of Hematology & Blood Diseases Hospital, Chinamonoclonal_antibodyPhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Acquired Hemophilia A cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking Union Medical College Hospital
Phase 4BB
Rituximab
Peking Union Medical College Hospital
Phase 4BB
Tak-672
Takeda
Phase 2/3B
Emicizumab
University of Washington
Phase 2B
Bortezomib
Peking Union Medical College Hospital
Phase 2CCC
Obi-1
Baxalta now part of Shire
Phase 2/3CCC
Susoctocog Alfa
Takeda
UnknownD

Same molecule, other indications

Daratumumab is also rated in:

plasma cell myelomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
smoldering plasma cell myelomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
diffuse large B-cell lymphomaActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →